Chong Kun Dang Pharmaceutical

Diversified pharma

185750 · KOSPI · South Korea

Public Market Listing

185750KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for Chong Kun Dang Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(9 total)
9Total Assets
1Approved
3Phase 3 / Filed
5Phase 1–2 / Early
9Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Approved
GABA-A receptorSmall molecule
Epilepsy
CKD-701(Lucenbies)No recent activity
Phase 3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Phase 3
PPAR-gammaSmall molecule
Type 2 Diabetes
Phase 3
Adenosine A3 receptor
MASH / NASHHepatocellular Carcinoma
CKD-506No recent activity
Phase 2
HDAC6 (Histone deacetylase 6)Small molecule
Rheumatoid Arthritis
Phase 1/2
METAntibody–drug conjugate
Non-Small Cell Lung Cancer
Carvedilol (CKD-385)No recent activity
Phase 1
Beta-adrenergic receptors (nonselective) and alpha-1 adrenergic receptor (antagonist)Small molecule
Hypertension
Phase 1
IL-4R-alphaMonoclonal antibody
Atopic Dermatitis
Phase 1
JAK1 / JAK3Small molecule
Rheumatoid Arthritis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
December 2029 (1)
CKD-703Phase 1/2Advanced Solid Tumors, Non-Small Cell Lung Cancer
Est. primary completion 2029-12 · NCT07439094 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 April 2026Topline resultNamodenosonNamodenoson Phase 2a pancreatic cancer data announced

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.2B———report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.2B———report ↗
2023-FY$1.3B———report ↗